INDICATIONS AND USAGE
If you are a patient experiencing problems with a Sanofi US product, please contact Sanofi US at .
The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.
Back to the top ▲
© 2020 sanofi‐aventis US LLC. All rights reserved.
|
|
This site is intended for use by US Healthcare Professionals only.
MAT-US-2006908-v2.0-10/2020 Last Updated: October 2020
Please note: By clicking on this link, you will be leaving this Sanofi US website and going to another, entirely independent, website. Sanofi US provides these links as a service to their website visitors and users; however, the Company takes no responsibility for the information on any website but their own.
Click the “Continue” button below to go to the page you requested or click “Cancel” to remain on this page.
IMPORTANT SAFETY INFORMATION
WARNING: FETAL TOXICITY
See full Prescribing Information for AVAPRO and AVALIDE for complete Boxed Warnings. When pregnancy is detected, discontinue AVAPRO or AVALIDE as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.